Arrhythmic risk stratification in ischemic, non-ischemic and hypertrophic cardiomyopathy: A two-step multifactorial, electrophysiology study inclusive approach

Figure 1 The PRESERVE EF[24] study’s two-step arrhythmic risk stratification algorithm. In the total sample of patients the estimated prevalence of major arrhythmic events (MAE) during the 32-mo follow-up was 1.5%. Implementation of the algorithm with the detection of the NIRFs in the first step determines the intermediate-risk subpopulation, with the MAE prevalence accounting for 4.4%. In the second step, the Programmed Ventricular Stimulation determines the actual high-risk subpopulation, with a prevalence reaching 22%. Of the 37 patients with implantable cardioverter defibrillator, there were 9 true activations during the 32-mo follow-up. Neither sudden cardiac death(SCD) nor inappropriate ICD activations were observed during follow-up. (Modified with permission from EHJ[24]).

Figure 2 Emerging new sudden cardiac death risk stratification paradigm. It is based on newer evidence, incorporating competing mortality assessments, as well as non-invasive and invasive tests. Non-invasive tests are performed before programmed ventricular stimulation (PVS) to assess the likelihood of functional circuit formation. PVS is pivotal in determining the potential for arrhythmia sustainability and guiding treatment, especially in intermediate and low‐risk patients. “Observe and Follow‐up” involves repeating tests for NIRF annually and PVS every 3–5 yr. NIRFs (noninvasive ECG risk factors) including the presence of late potentials (≥ 2/3 criteria), frequent premature ventricular contractions (≥ 30/h), non-sustained VT (≥ 1/24 h), abnormal heart rate turbulence (onset ≥ 0% and slope ≤ 2.5ms) and reduced deceleration capacity (≤ 4.5 ms), positive T wave alternans (≥ 65 μV), decreased heart rate variability (SDNN < 70ms), prolonged QT_c interval (> 440 ms in males and > 450 ms in females). (Modified after permission from ANE[60]).